Overview
Product name | Recombinant Human ICOS/CD278 Protein |
---|
Catalog No. | RP01401 |
---|
Description | Recombinant Human ICOS/CD278 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Glu21-Phe141) of human ICOS/CD278 (Accession #NP_036224.1) fused with a Fc, 6×His tag at the C-terminus. |
---|
Bio-Activity | Measured by its binding ability in a functional ELISA. Immobilized human B7-H2/ICOSLG at 1 μg/mL (100 μL/well) can bind Human ICOS/CD278 with a linear range of 2-14.8 ng/mL.
|
---|
Purity | > 95% by SDS-PAGE. |
---|
Endotoxin | <0.1EU/μg |
---|
Formulation | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
---|
Species | Human |
---|
Calculated MW | 40.53 kDa |
---|
Background
Inducible costimulator (ICOS), also called AILIM (Activation-Inducible Lymphocyte Immunomediatory Molecule) is a cell-surface receptor and belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4, and PD-1. The interaction of B7-H2/ICOS plays a critical role in Th cell differentiation, T?B cell interactions which are essential for the germinal center formation, and humoral immune responses, and as well as the production of cytokine IL-4. Also, ICOS is more potent in the induction of IL-10 production, a cytokine important for the suppressive function of T regulatory cells. The B7-1/B7-2--CD28/CTLA-4 and ICOS-B7RP-1 pathway provide key second signals that can regulate the activation, inhibition, and fine-tuning of T-lymphocyte responses. ICOS stimulates both Th1 and Th2 cytokine production but may have a preferential role in Th2 cell development. Moreover, The B7-1/B7-2-CD28/CTLA-4 and ICOS-B7RP-1 pathway has been suggested as being involved in the development of airway inflammation and airway hyperresponsiveness.
Product information
Synonym | AILIM; CD278; CVID1; ICOS; CD278; CVID1 |
---|
Expression Host | HEK293 cells |
---|
Tag | C-hFc&His |
---|
Swiss-Prot | |
---|
Gene ID | |
---|
Usage guide
Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
---|
Reconstitution | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
---|
* For research use only. Not for therapeutic or diagnostic purposes.